UK drugmaker says Emma Walmsley is underpaid compared with global competitors as it abandons diversity targets
US hedge fund shorts drugmaker as shares trade below price of a decade ago
Hedge fund’s short position is the biggest in the FTSE 100 group in more than a decade
Drugmaker pins hopes on launch of new medicines but key point is to avoid re-traumatising investors
UK pharma group raises long-term annual sales forecast to more than £40bn by 2031
IDRx tests treatment for digestive system cancer that affects 4,000 to 6,000 people a year in US
GSK, Sanofi and Moderna shares all sink after Donald Trump chooses vaccine sceptic as top US health official
UK pharma group posts ‘statistically significant’ trial results for Blenrep when combined with another treatment
UK pharma group’s shares fall 3% after third-quarter revenues miss expectations
Agreement over heartburn medicine should help to resolve concerns hanging over UK drugmaker
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain
Emmanuel Hanon criticises former company’s drug after he raises $100mn for rival product
GSK and AstraZeneca plan final trials to upgrade propellants that cause much of the sector’s carbon footprint
Analysts often err on side of extreme caution — but overreactions can generate potential opportunities
UK pharmaceutical group forecasts 7-9% revenue growth this year on strong performance from cancer and HIV drugs
Pharma groups could see almost threefold drop in demand due to US health official decision, says Airfinity
New agreement hands UK drugmaker control of developing jabs and provides cash injection for German group
Pharma group dealt another blow following decision by British to award vaccine contract to rival Pfizer
Brent Wisner, who won billions of dollars against Bayer, has received a big boost in Zantac cancer case
Litigation over Zantac is only one of several doubts the UK pharma group needs to overcome
Ruling means plaintiffs can present evidence alleging link between heartburn drug and cancer
Judge rules experts’ evidence admissible, leaving route open for 72,000 cancer sufferers to bring cases
Sale of 4.2% holding raises £1.25bn for pharmaceutical group as it shifts focus to high-value drugs
GSK joins UK government in committing £130mn to tackle growth of antimicrobial resistance
Quarterly results beat expectations and signal strong start for pharma group
